United States

Analyst Research

Report Title Price
Provider : Stock Traders Daily
Provider : Reuters Investment Profile
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Reports patients with diffuse Large B-Cell Lymphoma receiving Oral REVLIMID with Standard R-CHOP Achieved 98 pct Overall Response Rate and 80 pct complete Response Rate

Tuesday, 19 Aug 2014 07:30am EDT 

Celgene Corp:Says results of study evaluating combination of REVLIMID (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published.Says in phase II, open label, single arm study, by Dr. Grzegorz Nowakowski of the Mayo Clinic, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles.Says all patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout.Says primary endpoint was event-free survival (EFS) with secondary endpoints of progression free survival (PFS) and overall survival (OS).Says one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP.Says of the 64 patients enrolled, 60 were eligible for response evaluation.These patients, the overall response (OR) rate was 98 pct (59/60) with 80 pct (48/60) achieving a complete response (CR).Says 24-month EFS, which was identical to PFS, and OS rates were 59 pct (48-74 pct) and 78 pct (68-90 pct), respectively (95 pct CI).